Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial
Authors
- Chao Zhou (ORCID: https://orcid.org/0000-0002-9959-9337)
- Junhui Ye (ORCID: https://orcid.org/0000-0001-8192-8502)
- Guifei Yao (ORCID: https://orcid.org/0000-0002-0749-2306)
- Wei Wang (ORCID: https://orcid.org/0000-0002-4128-6450)
- Guixian Wu (ORCID: https://orcid.org/0000-0003-4339-2633)
- Ling Lin (ORCID: https://orcid.org/0000-0002-5338-8446)
- Dongqing Lv (ORCID: https://orcid.org/0000-0001-8226-9596)
- Haihua Yang (ORCID: https://orcid.org/0000-0001-5549-8633)
- Wujun Luo
- Xiaomai Wu (ORCID: https://orcid.org/0000-0002-1382-5234)
- Meifang Chen (ORCID: https://orcid.org/0000-0003-1899-6443)
- Ziran Chen (ORCID: https://orcid.org/0000-0003-1113-7697)
Institutions
- Wenzhou Medical University (CN)
- Zhejiang Taizhou Hospital (CN)
- Taizhou University (CN)
Funders
- European Society for Medical Oncology
- Science and Technology Program of Zhejiang Province